---
title: "UBS Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278719957.md"
description: "UBS analyst Graham Doyle has maintained a Hold rating on Carl Zeiss Meditec (0DHC) with a price target of €25.00. Doyle, who has an average return of -1.4% and a 51.88% success rate, focuses on the Healthcare sector. The analyst consensus for Carl Zeiss Meditec is also a Hold, with a higher price target consensus of €31.10."
datetime: "2026-03-11T12:18:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278719957.md)
  - [en](https://longbridge.com/en/news/278719957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278719957.md)
---

# UBS Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)

UBS analyst Graham Doyle maintained a Hold rating on Carl Zeiss Meditec today and set a price target of €25.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Doyle is an analyst with an average return of \-1.4% and a 51.88% success rate. Doyle covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care AG & Co. KGaA, Fresenius SE & Co. KGaA, and Siemens Healthineers AG.

Carl Zeiss Meditec has an analyst consensus of Hold, with a price target consensus of €31.10.

### Related Stocks

- [AFX.DE](https://longbridge.com/en/quote/AFX.DE.md)

## Related News & Research

- [Carl Zeiss Meditec (0DHC) Gets a Sell from J.P. Morgan](https://longbridge.com/en/news/286208300.md)
- [ZAWYA: Sidra Medicine advanced Imaging Core recognized as ZEISS labs@location Reference Customer](https://longbridge.com/en/news/286269565.md)
- [15:45 ET"Lean" Strengthens Saudi Arabia's Presence in Global Digital Health and Precision Medicine Ecosystems](https://longbridge.com/en/news/286811787.md)
- [05:54 ETTermHub™ Launches New Managed FHIR Offering for SDOs](https://longbridge.com/en/news/287042225.md)
- [A Look At SCHOTT Pharma KGaA (XTRA:1SXP) Valuation After Weaker Profitability In Latest Earnings](https://longbridge.com/en/news/287181929.md)